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Endocrine-disrupting chemicals (EDCs) are exogenous substances interfering with hor-
mone biosynthesis, metabolism, or action, and consequently causing disturbances in
the endocrine system. Various pathways are activated by EDCs, including interactions
with nuclear receptors (NRs), which are primary targets of numerous environmental
contaminants. The main NRs targeted by environmental contaminants are the estrogen
(ER α, β) and the androgen (AR) receptors. ERs and AR have pleiotropic regulatory roles
in a diverse range of tissues, notably in the mammary gland, the uterus, and the prostate.
Thus, dysfunctional ERs and AR signaling due to inappropriate exposure to environmental
pollutants may lead to hormonal cancers and infertility. The pregnane X receptor (PXR) is
also recognized by many environmental molecules. PXR has a protective role of the body
through its ability to regulate proteins involved in the metabolism, the conjugation, and the
transport of many exogenous and endogenous compounds. However, the permanent
activation of this receptor by xenobiotics may lead to premature drug metabolism, the
formation, and accumulation of toxic metabolites and defects in hormones homeostasis.
The activity of other NRs can also be affected by environmental molecules. Compounds
capable of inhibiting or activating the estrogen related (ERRγ), the thyroid hormone (TRα,
β), the retinoid X receptors (RXRα, β, γ), and peroxisome proliferator-activated (PPAR α,
γ) receptors have been identified and are highly suspected to promote developmental,
reproductive, neurological, or metabolic diseases in humans and wildlife. In this review,
we provide an overview of reporter cell lines established to characterize the human NR
activities of a large panel of EDCs including natural as well as industrial compounds such
as pesticides, plasticizers, surfactants, flame retardants, and cosmetics.
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Introduction
Human nuclear receptors (NRs) are a family of 48 transcription factors, many of which have
been shown to be activated by endogenous ligands. NRs regulate cognate gene networks
involved in key physiological functions such as cell growth and differentiation, development,
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FIGURE 1 | General nuclear receptor structure and function. (A) Structural
organization of NRs. NRs comprise six domains, including a N-terminal
activation function domain, a central DNA binding domain, and a C-terminal
ligand-binding domain carrying a ligand-dependant transcriptional function. (B)
Schematic model of NR function. Before ligand binding, type I NRs form inactive
complexes with chaperone proteins in the cytoplasm (AR) or in the nucleus (ERs)
whereas type II NRs (RXR heterodimers) are bound to their target genes with
corepressors. Ligand binding results in the dissociation of chaperone proteins
and binding and activation to target genes for type I NRs. Ligand binding results
in corepressors release and coactivator recruitment for type II NRs.
homeostasis, or metabolism (1, 2). As a consequence, inappropri-
ate exposure to environmental pollutants, which have the ability
to substitute for natural ligands, can cause proliferative, repro-
ductive, and metabolic disorders, including hormone-dependent
cancers, infertility, diabetes, or obesity.
NRs are transcriptional regulators comprising several domains,
including a N-terminal activation function domain (AF-1), a
central DNA-binding domain (DBD), and a C-terminal ligand-
binding domain (LBD) carrying a ligand-dependent transcrip-
tional activation function (AF-2) (2) (Figure 1A). When unas-
sociated with their ligand, type I NRs form inactive complexes
with chaperone proteins in the cytoplasm, whereas type II NRs are
located in the nucleus and bind to the DNA response elements of
their target genes along with corepressors (Table 1; Figure 1B).
Ligand binding triggers major conformational changes in the
receptor LBD that lead to the dissociation of chaperones and core-
pressors, nuclear translocation and DNA binding of type I NRs,
and recruitment of coactivators, thus initiating gene transcription.
In presence of agonists in the ligand-binding pocket, corepressors
dissociate and the recruitment of transcriptional coactivators is
favored (3–5). Reciprocally, interaction with antagonists avoids
TABLE 1 | Nuclear receptor characterization.
NR Cellular localization
in absence of ligand
Active form
ERα (NR3A1) Nuclear Homodimer
ERβ (NR3A2) Nuclear Homodimer
AR (NR3C4) Cytoplasmic Homodimer
ERRγ (NR3B3) Nuclear Monomer
PPARα (NR1C1) Nuclear RXR heterodimer
PPARγ (NR1C3) Nuclear RXR heterodimer
TRα (NR1A1) Nuclear RXR heterodimer
TRβ (NR1A2) Nuclear RXR heterodimer
PXR (NR1I2) Nuclear RXR heterodimer
RXRα (NR2B1) Nuclear Heterodimer or homodimer
RXRβ (NR2B2) Nuclear Heterodimer or homodimer
RXRγ (NR2B3) Nuclear Heterodimer or homodimer
association with coactivators and enables corepressors recruit-
ment (3–5). The LBD also contributes to the modulation of the
N-terminal AF-1 through interdomain crosstalk, which enable
AF-1 and AF-2 domains to recruit coactivators individually or in
a synergistic manner (6–8).
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Endocrine-disrupting chemicals (EDCs) are exogenous sub-
stances that interfere with the function of hormonal systems
and produce a range of developmental, reproductive, neurolog-
ical, immune, or metabolic diseases in humans and wildlife (9,
10). Many EDCs are man-made chemicals produced by indus-
try and released into the environment as, for example, bisphe-
nols, phthalates, pesticides, organotins, flame retardants, poly-
chlorinated biphenyls, dioxins, or alkylphenols. EDCs can also
be naturally produced by plants or fungus, like the genistein and
daidzein phytoestrogens, or the zealenone mycoestrogen. Popula-
tion exposure to EDCs is very variable in both quantity and quality
according to the area they live in. Agricultural and industrialized
areas are typically prone to contamination by a broad range of
chemicals that may seep into the soil and groundwater. Living
organisms are being exposed to these chemicals through ingestion
of contaminated food and water, breathing of contaminated air,
or direct contact with a contaminated soil. People working with
pesticides, fungicides, and industrial chemicals are particularly
exposed to these toxic substances and thus have a higher risk of
developing reproductive or endocrine disorders. EDCs affect the
endocrine system of organisms in various ways, like, for instance,
by mimicking natural hormones activity, antagonizing their
action, or modifying their synthesis, metabolism, and transport.
Pathways activated by these substances include stimulation of
membrane receptors and the aryl hydrocarbon receptor, and stim-
ulation of enzymatic machineries implicated in hormone biosyn-
thesis/metabolism. However, the majority of reported harmful
effects of EDCs have been attributed to their interference with
hormone signaling mediated by nuclear receptors (11–14). Most
original studies have focused on NRs involved in reproductive
processes, in particular ERs and AR, but recent data have shown
that EDCs can act as nano- to micromolar ligands for many other
receptors including the activity of pregnane X receptor (PXR),
ERRγ, TRs, retinoid X receptors (RXRs), PPARα, or PPARγ.
The need to screen thousands of chemicals for their humanNRs
interactions leads several laboratories including ours to develop
robust reporter gene assays with high sensitivity, selectivity, and
responsiveness for NR ligands. Unlike other in vitro techniques
including ligand-binding assays and endogenous gene expression
measurement by quantitative RT-PCR, the stable expression of
reporter genes creates robust and reproducible and easy-to-handle
cellular models, which are easy transferable from one laboratory
to another. Here, we review recent studies in which we have
characterized NR activity of EDCs using reporter cells.
Estrogen Receptors, Estrogen-Responsive
Reporter Cell Lines, and Environmental
Estrogens
ERα (NR3A1) and ERβ (NR3A2) are nuclear receptors for the
sex hormone 17β-estradiol (E2), which play an important role
in the growth and maintenance of various tissues such as the
uterus, mammary gland, bones, or the cardiovascular system.
Those ERs are broadly distributed throughout the body and dis-
play both distinct and overlapping expression patterns in tissues
(15). Indeed, ERα is preferentially expressed in the uterus, kidney,
liver, and heart, whereas ERβ is primarily expressed in the ovary,
prostate, gastrointestinal tract, lung, bladder, and hematopoietic
and central nervous systems (16). However, ERα and ERβ are
also coexpressed in numerous tissues such as themammary gland,
adrenal, thyroid, bones, and some regions of the brain.
Interestingly, when ERs are coexpressed, ERβ exhibits an
inhibitory action on ERα-mediated gene expression (17, 18) so
that ERβ has been shown to antagonize several ERα-mediated
effects including fat reduction and cellular proliferation in breast,
uterus, or prostate (19–21). It is thus pertinent to ask whether
EDCs have different selectivities for ERs. Although the LBDs of
ERα and ERβ share a high degree of homology in their primary
amino acid sequence and are very similar in their tertiary archi-
tecture (4), some ERα- and ERβ-selective pharmaceutical ligands
have been identified (22).
To characterize human ER activity of chemicals, different
reporter cell lines have been generated by the scientific commu-
nity (Table 2; Figure 2). The first strategy consisted of stably
transfecting breast (MCF-7, T47-D) or ovarian cancer (BG1) cells,
which express endogenously ERα with an estrogen-regulated
luciferase gene (23–26). These cell lines were extensively used to
measure ERα activity of pure chemicals or environmental sam-
ples. However, because they do not express ERβ, another strategy
consisted of expressing ERα or ERβ in ER-negative cell lines (23,
27–29). In our case and in order to obtain comparable cell lines,
we first transfected the estrogen-responsive reporter gene in Hela
cells, which does not express ERs. In a second step, cells stably
transfected with the ERE-luciferase plasmid (HELN cells) were
transfected with an ERα or ERβ construct (23). Using these cell
lines, we have characterized the ERα and ERβ potency of ER
environmental ligands. These molecules are highly heterogenous
and include few high affinity ligands (EC50 values between 10 pM
and 1 nM) (Table 3). These potent estrogens are pharmaceutical
agents contained in contraceptive pills (ethinyl estradiol, hexe-
strol), human estrogens (estradiol, estrone, estriol) (30), or the
mycoestrogen zearalenone and its metabolites (31). Many other
environmental compounds interact with ERs with medium to low
affinity (EC50 values between 1 nM and 10 µM) (Table 3). Phytoe-
strogens are plant-derived substances that have estrogenic activity
(16). Genistein, the principal phytoestrogen in soy, is an agonist
for both ERs, with, however, amarked preference for ERβ (27, 30).
Some pesticides like dichloro-diphenyltrichloroethane (DTT),
methoxychlore, chlordecone, vinclozolin, and their metabo-
lites act as estrogenic chemicals. Interestingly, chlordecone and
methoxychlor display ERα agonistic but ERβ antagonistic activ-
ity. Finally, cosmetics like conservative parabens and UV-screens
benzophenones, and many industrial compounds such as bisphe-
nols and their halogenated derivatives, alkylphenols, and phtha-
lates display estrogenic activity (32). For these compounds, the
affinity for ERs is closely dependent of their structure. The estro-
genic potency of parabens is clearly dependent of the alkyl chain
length. Propyl and butyl parabens are more active than methyl
and ethyl parabens (33). Similarly, alkylphenols with long chain
(C8–C9) have better affinity for ERs than alkylphenols with short
chain. In a similar manner, the number and the position of the
hydroxyl groups of benzophenones have a strong impact on their
potency (34). Finally, the nature of additional groups of bisphenols
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TABLE 2 | Nuclear receptor reporter cell lines developed to screen EDCs.
NR Cell type Active NR Reporter gene Reference
ERα (NR3A1) MCF-7 hERα ERE-β-globin-luciferase (23)
T47-D hERα ERE3-TATA-luciferase (26)
BG1 hERα ERE3-TATA-luciferase (25)
BG1 hERα ERE3-TATA-luciferase (24)
U2OS hERα ERE3-TATA-luciferase (29)
293 hERα ERE-MMTV-phosphatase (27)
HS578T hERα ERE3-TATA-luciferase (28)
HeLa hERα ERE-β-globin-luciferase (23)
HeLa ∆AB-hERα ERE-β-globin-luciferase (30)
ERβ (NR3A2) U2OS hERβ ERE3-TATA-luciferase (49)
293 hERβ ERE-MMTV-phosphatase (27)
HS578T hERβ ERE3-TATA-luciferase (28)
HeLa hERβ ERE-β-globin-luciferase (23)
HeLa ∆AB-hERβ ERE-β-globin-luciferase (30)
AR (NR3C4) PC3 hAR, hGR MMTV-Luciferase (41)
MDA-MB-453 hAR, hGR MMTV-Luciferase (40)
U2OS hAR ARE3-TATA-luciferase (49)
HeLa hARα ERα (DBD) ERE-β-globin-luciferase (35)
ERRγ (NR3B3) HeLa GAL4 (DBD)-hERRγ (LBD) GALRE5-β-globin-luciferase (35)
PPARα (NRC1) HeLa GAL4 (DBD)-hPPARα (LBD) GALRE5-β-globin-luciferase (78)
PPARβ (NRC2) HeLa GAL4 (DBD)-hPPARβ (LBD) GALRE5-β-globin-luciferase (78)
PPARγ (NRC3) U2OS hPPARγ1 PPARRE3-TATA-luciferase (77)
U2OS hPPARγ2 PPARRE3-TATA-luciferase (77)
HeLa GAL4 (DBD)-hPPARγ (LBD) GALRE5-β-globin-luciferase (78)
TRα (NR1A1) GH3 *rTRα, *rTRβ DR42-TATA-luciferase (82)
PC12 **cTRα DR44-TATA-luciferase (83)
HeLa GAL4 (DBD)-*rTRα (LBD) GALRE5-β-globin-luciferase (84)
TRα (NR1A2) HeLa GAL4 (DBD)-*rTRβ (LBD) GALRE5-β-globin-luciferase (84)
PXR (NR1I2) HepG2 hPXR CYP3A4-luciferase (96)
HepG2 hPXR CYP3A4-luciferase (97)
HepG2 hPXR CYP3A4-luciferase (98)
HepG2 hPXR CYP3A4-luciferase (99)
HeLa GAL4 (DBD)-hPXR (LBD) GALRE5-β-globin-luciferase (100)
RXRα (NR2B1) HeLa GAL4 (DBD)-mRXRα (LBD) GALRE5-β-globin-luciferase (108)
WT, Wild type NR; ∆AB, AB domain-deleted NR; ERα DBD, NR within the DBD were replaced by the hERα DBD; GAL4 DBD-NR LBD, chimeric NR constituted by the yeast GAL4 DBD
fused to the NR LBD; MMTV, mouse mammary tumor virus; CYP3A4, cytochrome P4510 3A4; *r, rat; **chicken.
is also very important for the estrogenic activity of these com-
pounds (35–37). As an example, Bisphenol S of which the two
phenolic groups are linked by a sulfur dioxide (SO2) group is 100-
fold less potent for ERs than Bisphenol AF of which the phenolic
groups are linked by a C(CF3)2 group (35).
Interestingly, using HELN cell lines expressing N-terminal
domain-deleted ERα and ERβ, we have shown that the agonistic
efficacy of environmental estrogens depends on the receptor
subtype and vary drastically among molecules from full agonists
to weak agonists or antagonists. Whereas benzophenone-2
and 4-tert-alkylpenol acted as full agonists for both subtypes,
ferutinine, α-zearalanol, bisphenol C (BPC), tetrachloro
BPA (TCBPA), chlordecone, 2,2-bis(p-hydroxyphenyl)-1,1,1-
trichloroethane (HPTE) and 2,40 diphenyldichloroethylene
(2,40-DDE) are selective activators of ERα. On the contrary,
BPA and butylparaben activated ERβ more efficiently than ERα.
These results indicated that environmental estrogens also acted
in a subtype-specific manner as full agonists, partial agonists,
or antagonists by using different combinations of the N- and
C-terminal activation functions of hERα and hERβ.
Androgen Receptor, Androgen Responsive
Reporter Cell Lines, and Environmental
Anti-androgens
Androgen receptor (AR) (NR3C4) plays a crucial role in the
regulation of target genes expression in physiological processes
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FIGURE 2 | NR reporter cell establishment strategy. Different strategies to
establish reporter cell lines have been used. The first consisted to transfect
NR-positive cells with a NR-responsive reporter gene. When several NRs are
able to activate the same promoter in a cell, an alternative strategy consists to
transfect a chimeric NR-expressing plasmid. Cells are transfected by plasmids
enabling the expression of the chimeric construct of the yeast GAL4 DBD fused
to the NR LBD and the luciferase under the control of GAL4. Cells (ER negative)
can also be transfected by a plasmid enabling the expression of a chimeric NR
in which the DBD was replaced by the one of ERα and the luciferase gene
under the control of estrogens. The third strategy consisted to transfect
NR-negative cells in a first step by an NR-responsive reporter gene and in a
second step by an NR-expressing plasmid.
like development and differentiation of the male embryo and
spermatogenesis initiation and maintenance, as well as neuro-
endocrine system functioning (38). In the absence of ligands, AR
is essentially localized in the cytoplasm. Binding to androgens
enables HSPs dissociation and AR translocation to the nucleus.
The AR LBD strongly contributes to the modulation of the N-
terminal AF-1 through ligand-induced interdomain association.
Furthermore, in AR, it appears that AF-1 predominates over AF-
2 (39). The presence of androgens is essential for the regulation
of male embryo development and differentiation processes and
spermatogenesis initiation and maintenance. Like to estrogens,
androgens influence also the development and growth of the
mammary gland in women. Treatment of animals and cultured
cells with androgens activates AR and has either inhibitory or
stimulatory effects on genes transcription that are under steroid
hormone control. Anti-androgens can disrupt this process.
To characterize human AR activity of chemicals, different
reporter cell lines have been generated (Table 2). MDA-MB-453
(AR and GR positive) breast cancer cells have been transfected
by the steroid responsive MMTV-luciferase plasmid (40). Two
other reporter cell lines have been established by co-transfecting
PC3 (41) and CHO (42) AR-negative cells with an MMTV-
luciferase gene and an AR expressing plasmid. MDA-MB-453
(MDA-KB2) and PC3 (PALM) cells were extensively used to test
anti-androgenicity of chemicals (31, 34, 36, 43–46) and environ-
mental samples (47, 48). A problem with testing androgenicity is
the activation of the reporter gene by GR, which is endogenously
expressed in these cells. In order to improve the selectivity of the
reporter cell line for testing androgenic agonist activity, van der
Burg et al. (49) transfect U2OS cells, which express low amounts
of GR with an androgen-responsive luciferase gene and an AR
expressing plasmid (49). Another strategy developed by our group
was to express in HELN (HeLa ERE-Luc) cells, a chimeric AR
in which the DBD was replaced by the one of ERα (35). In
these cells, only the AR ERα DBD is able to activate luciferase
expression.
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TABLE 3 | EDCs and their NR targets.
EDCs NR targets EC50 range Lead compound Nature
Mycoestrogens ERα (NR3A1) 0.01–1 nM Zearalenone Full agonist
ERβ (NR3A2) 0.01–1 nM Zearalenone Partial agonist
AR (NR3C4) 1–10 µM Zearalenone Antagonist
PXR (NR1I2) 1–10 µM Zearalenone Full agonist
Phytoestrogens ERα (NR3A1) 0.1–1 µM Genistein Full agonist
ERβ (NR3A2) 0.01–0.1 µM Genistein Partial agonist
Parabens ERα (NR3A1) 1–10 µM Butyl paraben Full agonist
ERβ (NR3A2) 1–10 µM Butyl paraben Full agonist
Benzophenones ERα (NR3A1) 0.1–1 µM Benzophenone-2 Full agonist
ERβ (NR3A2) 0.1–1 µM Benzophenone-2 Full agonist
AR (NR3C4) 1–10 µM THB Antagonist
Bisphenols ERα (NR3A1) 0.01–1 µM BPA Partial agonist
ERβ (NR3A2) 0.01–1 µM BPA Partial agonist
AR (NR3C4) 0.01–1 µM BPA Antagonist
ERRγ (NR3B3) 0.001–0.1 µM BPA Agonist
PXR (NR1I2) 1–10 µM BPA Agonist
Halogenated bisphenols ERα (NR3A1) 0.1–10 µM TetrachloroBPA Partial agonist
ERβ (NR3A2) 0.1–10 µM TetrachloroBPA Partial agonist
PPARγ (NR1C3) 1–10 µM TetrabromoBPA Partial agonist
TRα (NR1A1) 1–10 µM TetrabromoBPA Antagonist
TRβ (NR1A2) 1–10 µM TetrabromoBPA Antagonist
Alkylphenols ERα (NR3A1) 0.01–1 µM 4-tert-Octylphenol Agonist
ERβ (NR3A2) 0.01–1 µM 4-tert-Octylphenol Partial agonist
AR (NR3C4) 1–10 µM 4-tert-Octylphenol Antagonist
ERRγ (NR3B3) 1–10 µM 4-tert-Octylphenol Antagonist
PXR (NR1I2) 1–10 µM 4-tert-Octylphenol Agonist
Phthalates ERα (NR3A1) 1–10 µM BBP Agonist
ERβ (NR3A2) 1–10 µM BBP Partial agonist
PPARα (NR1C1) 1–100 µM MEHP Agonist
PPARγ (NR1C3) 1–100 µM MEHP Agonist
Perfluorinated compounds PPARα (NR1C1) 1–100 µM PFOA Agonist
PPARγ (NR1C3) 1–100 µM PFOA Agonist
Pesticides ERα (NR3A1) 0.1–10 µM 2,40-DDE Agonist
ERβ (NR3A2) 0.1–10 µM 2,40-DDE Partial agonist
AR (NR3C4) 0.1–1 µM M2 vinclozolin Partial agonist
PXR (NR1I2) 0.1–10 µM Pretilachlor Agonist
Organotins PPARγ (NR1C3) 1–10 nM TBT Partial agonist
RXRα (NR2B1) 1–10 nM TBT Agonist
THB, trihydroxy-benzophenone; BPA, bisphenol A; BBP, benzyl butyl phthalate; MEHP, mono ethyl hexyl phthalate; PFOA, perfluorinated octanoic acid; DDE,
dichlorodiphenyldichloroethylene; TBT, tributyltin.
Using these reporter cell lines, we have measured the
(anti)androgenicity of environmental compounds. Most of the
compounds described to be estrogenic are also anti-androgenic.
The most potent of them are zearalenone and some of its metabo-
lites (36), M2 vinclozolin metabolite (44), 2,40-DDE (50), 2,3,4-
trihydroxy-benzophenone (THB) (34), and BPC (35) (Table 3).
Estrogen-Related Receptor γ, ERRγ
Reporter Cell Lines, and Their
Environmental Ligands
The ERR subfamily of orphan receptors is closely related to ERs
and includes three members, ERRα (NR3B1), ERRβ (NR3B2),
and ERRγ (NR3B3) (51). ERRα is expressed at higher levels than
the two other ERR subtypes and is detected in the heart, kidney,
intestinal tract, skeletal muscle, and brown adipose tissue. ERRβ
and ERRγ aremainly expressed in the heart and the kidney (52). It
has been suggested that ERRs may play a central role in regulating
energy metabolism (53). Meanwhile, the rise in the incidence
of metabolic syndromes correlates with the increased use and
distribution of industrial chemicals suspected of playing a role
in generation of obesity (54). Altogether, these data suggest that
EDCs and ERRγ may be involved in this epidemic crisis.
Additionally, it has been demonstrated that ERRγ can interfere
with estrogen signaling (51, 55) by recognizing ERs DNA-binding
elements and activating ERs target gene (56, 57). Expression of
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ERRγ is associated with favorable prognosis of breast cancer (58)
and exogenous overexpression of ERRγ in a prostate cancer cell
line inhibits proliferation (59). Furthermore, treatment with an
ERRβ/γ agonist has been shown to promote this antiproliferative
effect. To date, ERRγ has not been shown to interactwith any phys-
iologically relevant small molecules, suggesting that this receptor
manifest constitutive activity (60, 61). Indeed, crystallographic
analyses of ERRγ indicated that these receptors adopt the tran-
scriptionally active conformation in the absence of any ligand (60).
To our knowledge, only our group established an ERRγ reporter
cell line (Table 2). In order to characterize the interaction of
environmental compounds with human ERRγ, we first developed
a HeLa cell line expressing the luciferase gene under the control
of the yeast GAL4 transcription factor (HG5LN cells). In a second
step, these cells were stably transfectedwith a plasmid enabling the
expression of the chimeric construct of the yeast GAL4DBD fused
to the ERRγ LBD (35). With this cell line, we were able to confirm
that BPA, bisphenol E (BPE), and others phenols asmedium (EC50
values in the 10–100 nM range) binders of ERRγ (62). To date, the
other compounds screened for affinity or activity on ERRγ were
known endocrine disruptors with estrogen-like activity. Most of
them are not potent agonists (63) or antagonists (61, 64, 65). Their
EC50 or IC50 values are in the micromoles range.
Peroxysome Proliferator-Activated
Receptors, PPAR-Responsive Reporter
Cell Lines, and Environmental PPAR
Ligands
The NR subfamily of peroxisome proliferator-activated receptors
(PPARs) includes three members, PPARα (NR1C1), PPARβ/δ
(NR1C2), and PPARγ (NR1C3). These receptors bind to PPAR-
responsive DNA regulatory elements in the form of heterodimers
with RXR. PPARs have distinct tissue distributions and physiolog-
ical roles (66–68). PPARα is preferentially expressed in the heart,
liver, and brown adipose tissue, whereas PPARβ/δ is ubiquitously
expressed. They both play an important role as activators of fatty
acid oxidation pathways and thus in the regulation of energy
homeostasis. Furthermore, it has been shown that PPARα stim-
ulates cholesterol catabolism, heme synthesis, and participates
in the control of urea synthesis and amino acid metabolism.
PPARβ/δ is involved in the control of cell proliferation and dif-
ferentiation and is required for gut and placental development.
PPARγ, for its part, is highly expressed in adipose tissues and
plays a key role in regulating adipogenesis (69), lipid metabolism,
and glucose homeostasis by improving insulin sensitivity (70).
PPARs bind and respond to dietary fatty acids and various lipid
metabolites, including eicosanoids, prostaglandins, and oxidized
phospholipids (67, 71).
In accordance with their tissue distributions and roles as sen-
sors of lipids/fatty acids levels, in regulating fatty acid catabolism,
and in lipid storage, all three PPARs are thought to be strongly
involved in the metabolic syndrome. However, in light of the
particular role of PPARγ in adipose tissue development andmain-
tenance, it has been suggested that the disruption of regulatory
pathways controlled by PPARγ may be specifically implicated
in the onset of diabetes and obesity (11). As a matter of fact,
activation of PPARγ by some xenobiotic compounds has been
shown to stimulate adipogenesis in vitro and in vivo by promoting
the differentiation of preadipocytes of the fibroblastic lineage
into mature adipocytes (72–75). This contributed to the “obeso-
gen hypothesis” stating that the growing obesity epidemic due
to the imbalance between caloric intake and expenditure could
also implicate chemicals, so-called “obesogens,” which directly or
indirectly increase fat accumulation and obesity (74, 76).
To characterize the human PPARγ activity of chemicals, Gijs-
bers et al. (77) stably transfected U2OS cells, which express
low amounts of PPAR with a PPAR-responsive luciferase gene
and PPARγ1- and PPARγ2-expressing plasmids (Table 2). In
our group, we have developed a strategy similar to the one we
developed for ERRγ. To obtain comparable cell lines, we trans-
fected HG5LN cells (HeLa GAL4RE-luciferase) with plasmids
expressing the LBD of the three human PPARs fused to the
yeast GAL4 DBD (78). Using these cell lines, we were able to
characterize the PPARγ activity of TCBPA and tetrabrominated
BPA (TBBPA), perfluorooctanoic acid (PFOA), and mono(2-
ethylhexyl)phthalate (MEHP) (37, 73). TBBPA and TCBPA acti-
vate partially PPARγ with approximately 100-fold less potency
(EC50 values in the micromoles range) (Table 3) than the ref-
erence pharmaceutical compound rosiglitazone (EC50 value of
10 nM). Interestingly, while PFOA and MEHP are PPARα and
PPARγ agonists (EC50 values in the 1–100 µM range), TBBPA,
TCBPA, and their biotransformation products do not notably
impact PPARα and PPARδ. Using these cells, we also character-
ized the RXR–PPARγ activity of organotins (72). To assess the
specific effect of tributyltin (TBT) on RXR and PPARγ, cells were
co-incubated with saturating concentrations of CD3254 (RXR
agonist) or rosiglitazone (PPARγ agonist) and increasing concen-
trations of rosiglitazone, CD3254, or TBT. Like CD3254, TBT is
able to further activate the rosiglitazone-saturated heterodimer.
However, in contrast with rosiglitazone, TBT appears unable
to act in conjunction with CD3254 to enhance the activity of
RXR/PPARγ. TBT activates RXRα as efficiently as the full agonist
CD3254, whereas it behaves as a very weak PPARγ agonist.
Thyroid Receptors, Thyroid Responsive
Reporter Cell Lines, and Environmental TR
Ligands
The NR subfamily of thyroid receptors (TRs) includes two mem-
bers, TRα (NR1A1) and TRβ (NR1A2). Their tissue distributions
are relatively ubiquitous and the expression of these proteins
begins early in development (79). Thyroid hormones (THs) are
essential for the normal development, growth, and metabolism
of all vertebrates (79) and play a major role in neurogenesis and
brain function at all stages of development (80). THs are produced
by the thyroid. Tetra-iodothyronine (thyroxine or T4) and tri-
iodothyronine (T3) are the principal representatives of circulating
THs. In target cells, T4 is converted to T3, which is themost active
TH. Moreover, THs are key developmental and differentiation
hormones in all organs of the body, including the central nervous
system and the skeleton.
Several environmental chemicals can disturb the thyroid hor-
mone system by affecting synthesis, transport, metabolism, and
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cellular uptake (81). To characterize chemicals acting at the TR
level, different reporter cell lines have been generated (Table 2).
Freitas et al. (82) stably expressed a thyroid-regulated luciferase
gene in rat pituitary TR-positive cells (GH3). Jugan et al. (83) sta-
bly expressed a thyroid-regulated luciferase gene in rat PC12 cells
previously transfected by an avianTRα-expressing plasmid. In our
group, we developed a strategy similar to the onewe used for ERRγ
and PPARs reporter cells. HG5LN were transfected with plasmids
expressing GAL4 (DBD)-human TRs (LBD) (84). Using these cell
lines, we showed that BPA and its halogenated derivatives are TR
antagonists in the 1–100 µM range (84) (Table 3). Among the
other compounds that act through NR binding, Freitas et al. (82)
showed that hydroxylated BDEs and PCBs are TR agonists in the
1–10 µM range.
Pregnane X Receptor, PXR Responsive
Cell Lines, and PXR Environmental Ligands
Pregnane X receptor (NR1I2) is a broad-specificity sensor playing
a critical role in the regulation of phase I (CYP), phase II (con-
jugating), and phase III (ABC family transporters) detoxifying
enzymes, coordinately regulating steroid, drug, and xenobiotic
clearance in the liver and intestine (85). Activated PXR binds
to gene promoters as a heterodimer with RXR and triggers tar-
get genes expression such as cytochrome P450 3A4 (CYP3A),
UDP-glycosyltransferase (UGT1A1), and multidrug resistance
protein 1 (MDR1) (86). PXR plays an important role in pro-
tecting the endocrine system from EDCs by sensing concen-
tration increases of these chemicals and stimulating detoxifica-
tion pathways, resulting in a decreased interaction of EDCs with
other NRs. This PXR-driven elimination of xenobiotics confers
a positive role to the activation of this NR. On the contrary,
PXR activation can also prevent effects of hormones or drugs
by stimulating prematurely their metabolism, which could lead
to adverse interactions or harmful effects. Additionally, inac-
tive compounds can be metabolized into active metabolites that
could have deleterious consequences (87). On the other hand,
the activation of PXR has been linked to an increased risk of
cardiovascular (88), metabolic (89), and cancer diseases (90, 91).
Unlike most NRs that tend to be specialized in binding few
ligands with structural homologies, PXR binds a multitude of
drugs such as the antibiotic rifampicin (92), the anti-cancer taxol
(93), the anti-cholesterol SR12813 (94), the St John’s worth anti-
depressor hyperforin (95), and many more, reviewed in di Masi
et al. (86).
Since PXR is also able to bind environmental compounds, sev-
eral groups have established reporter cell lines to study their inter-
actions. Lemaire et al. (96), Ratajewski et al. (97), Raucy et al. (98),
and Sekimoto et al. (99) have developed similar cellular models
(Table 2). They are human hepatoma HEPG2 cells co-transfected
with a human PXR expression vector and the luciferase gene
driven by the human CYP3A4 promoter. Because we suspected
that expression of PXR could reduce the potency of compounds
that are metabolized by target genes of PXR (CYP3A4, UGT1A1,
or MDR1), we expressed GAL4 (DBD)-PXR (LBD) in HG5LN
cells (100). Using the HG5LN GAL4-PXR reporter cell line, we
have shown that a large number of environmental chemicals like
pesticides (101), natural and synthetic estrogens, alkylphenols
(102, 103), and polychlorinated biphenyls (103) are targets of
PXR. EC50 values of these compounds for PXR are generally in
the 1–100 µM range excepted for some pesticides (pretilachlor,
oxadiazon) exhibiting EC50 values are in the submicromolar range
(101).Wenoticed thatHG5LNGAL4-PXR cells aremore sensitive
for some chemicals (i.e., clotrimazol, transnonachlor) than the
HEPG2 PXR CYP3A4 cells (96, 101) (Table 3). This is proba-
bly due to the fact that the PXR chimeric receptor is unable to
activate the expression of detoxifying enzymes. On the contrary,
in HEPG2 PXR cells, the ligand can activate PXR, which in turn
increases itsmetabolism and reduce its intracellular concentration
during the assay.
Retinoid X Receptors, RXR Responsive
Cell Lines, and RXR Environmental Ligands
The NR subfamily of RXRs includes three members, RXRα
(NR2B1), RXRβ (NR2B2), and RXRβ (NR2B3). RXRs are par-
ticular since they represent heterodimerization partners for about
one-third of NRs and are therefore implicated in the regulation
of numerous signaling pathways in both ligand-dependent and
ligand-independent manners (104). RXRs form three different
types of dimers: RXR homodimer, permissive heterodimers, and
non-permissive heterodimers. The so-called “permissive” RXR
heterodimers are able to be activated when ligand binds to RXR,
even in the absence of the partner receptor ligand. On the con-
trary, non-permissive heterodimers cannot be activated by the
RXR ligand alone and RXR remain silent in absence of ligand for
the partner NR. However, in both cases, it has been reported that
RXR ligands and ligands of the partner receptors could act in a
synergistic manner to activate heterodimers (1, 105). The involve-
ment of RXR heterodimers in the regulation of multiple nuclear
signaling pathways signifies that RXR ligands can potentially exert
numerous harmful effects on human health. RXRs are activated by
9-cis retinoic acid as well as docosahexaenoic acid (106, 107).
Retinoid X receptor reporter cell lines established by co-
transfection with the GAL4RE-luciferase and the LBD of the three
mouse RXRs, fused to the yeast GAL4 DBD plasmids were estab-
lished by Nahoum et al. (108) (Table 1). In our group, in order to
determine if humanRXRcould also be activated by environmental
chemicals, we used the RXR-permissive PPARγ reporter cell line.
We thus demonstrated that TBT, triphenyltin, tripropyltin, and
dibutyltin are able to activate RXR at nanomolar concentrations.
Excepted organotins, we failed to identify environmental chemi-
cals with RXR activity.
Conclusion
Endocrine-disrupting chemicals are chemicals of great concern
because these compounds, which are ubiquitously present in
our daily environment, can cause adverse effects in humans and
wildlife. By deregulation of NR-mediated transcription, EDCs can
alter endocrine functions and cause infertility, malformations,
metabolic troubles, or increase incidence of cancers. Though ERs
are primary targets of EDCs, other members of the NR family,
including AR, ERRγ, PPARs, TRs, RXRs, and PXR have been
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shown to correspond to secondary targets of EDCs. The weak
structural relationships between EDCs and natural ligands make
their interactions with NRs poorly understood and hardly pre-
dictable. Therefore, it is necessary to characterize the deleterious
interactions between environmental compounds and NRs and
develop robust screening methods.
In vitro and cell-based screens designed to identify NR ligands
include binding assays using recombinant NR full length or LBD
or transcriptional assays using cells with stable transfection of
NR and a corresponding responsive luciferase gene. Cell-based
assays have the advantage of typically being high-throughput,
requiring less time and costs. In the present article, we review
the reporter cell lines that have been established to characterize
EDCs interaction with ERs, AR, ERRγ, PPARs, TRs, PXR, and
RXRs. Characterization of the harmful interaction between these
different NRs and environmental compounds is currently studied
in several laboratories for the assessment of toxic potential of large
numbers of chemicals.
Controversy remains about the EDCsmechanism of action and
low-dose effect. Recent studies have revealed additional EDCs
targets throughwhich EDCs can stimulate rapid cellular responses
at very low concentrations. These include membrane-associated
NRs (109, 110) and the G protein-coupled receptor 30 (111).
Development of robust in vitro screening methods for these new
EDCs targets is also very important.
Most of our current knowledge of EDCs action is based on
single molecule exposure in model systems in vitro or in vivo.
These efforts have therefore taken little account of a more
realistic situation in which humans are chronically exposed to
low doses of multiple EDCs, which are likely to act in an
additive, antagonistic, or synergistic manner through their com-
bined actions on various nuclear andmembrane-associated recep-
tors. Indeed, a growing number of studies indicate that human
risk assessment approaches based on single molecule exposure
underestimate the risk for adverse effects of chemicals (112).
Thus, one of the greatest future challenges in risk assessment
is to develop novel protocols to evaluate the toxicity of com-
plex mixtures of chemicals. In this regard, the robust in silico
screening methods, which are currently being developed for the
prediction of the harmful interaction between large numbers
of chemicals and their cellular targets, will be of great value
(35, 113–115).
References
1. Germain P, Chambon P, Eichele G, Evans RM, Lazar MA, Leid M, et al.
International union of pharmacology. LXIII. Retinoid X receptors. Pharmacol
Rev (2006) 58:760–72. doi:10.1124/pr.58.4.7
2. Gronemeyer H, Gustafsson JA, Laudet V. Principles for modulation of the
nuclear receptor superfamily. Nat Rev Drug Discov (2004) 3:950–64. doi:10.
1038/nrd1551
3. Bourguet W, Germain P, Gronemeyer H. Nuclear receptor ligand-binding
domains: three-dimensional structures, molecular interactions and pharma-
cological implications. Trends Pharmacol Sci (2000) 21:381–8. doi:10.1016/
S0165-6147(00)01548-0
4. Pike AC. Lessons learnt from structural studies of the oestrogen receptor. Best
Pract Res Clin Endocrinol Metab (2006) 20:1–14. doi:10.1016/j.beem.2005.09.
002
5. Renaud JP, Moras D. Structural studies on nuclear receptors. Cell Mol Life Sci
(2000) 57:1748–69. doi:10.1007/PL00000656
6. Benecke A, Chambon P, Gronemeyer H. Synergy between estrogen receptor
alpha activation functions AF1 and AF2 mediated by transcription inter-
mediary factor TIF2. EMBO Rep (2000) 1:151–7. doi:10.1093/embo-reports/
kvd028
7. Bommer M, Benecke A, Gronemeyer H, Rochette-Egly C. TIF2 mediates the
synergy between RARalpha 1 activation functions AF-1 and AF-2. J Biol Chem
(2002) 277:37961–6. doi:10.1074/jbc.M206001200
8. Wilson EM. Analysis of interdomain interactions of the androgen receptor.
Methods Mol Biol (2011) 776:113–29. doi:10.1007/978-1-61779-243-4_8
9. Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, Hauser R,
Prins GS, Soto AM. Endocrine-disrupting chemicals: an endocrine
society scientific statement. Endocr Rev (2009) 30:293–342. doi:10.1210/
er.2009-0002
10. Hotchkiss AK, Rider CV, Blystone CR, Wilson VS, Hartig PC, Ankley GT,
et al. Fifteen years after “Wingspread” – environmental endocrine disrupters
and human and wildlife health: where we are today and where we need to go.
Toxicol Sci (2008) 105:235–59. doi:10.1093/toxsci/kfn030
11. Swedenborg E, Ruegg J, Makela S, Pongratz I. Endocrine disruptive chem-
icals: mechanisms of action and involvement in metabolic disorders. J Mol
Endocrinol (2009) 43:1–10. doi:10.1677/JME-08-0132
12. TabbMM, Blumberg B. Newmodes of action for endocrine-disrupting chem-
icals.Mol Endocrinol (2006) 20:475–82. doi:10.1210/me.2004-0513
13. Janosek J, Hilscherova K, Blaha L, Holoubek I. Environmental xenobiotics and
nuclear receptors – interactions, effects and in vitro assessment.Toxicol In vitro
(2006) 20:18–37. doi:10.1016/j.tiv.2005.06.001
14. Toppari J. Environmental endocrine disrupters. Sex Dev (2008) 2:260–7.
doi:10.1159/000152042
15. Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and
where will they lead us? Endocr Rev (1999) 20:358–417. doi:10.1210/edrv.20.
3.0370
16. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, et al.
Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor
beta. Endocrinology (1998) 139:4252–63. doi:10.1210/endo.139.10.6216
17. LiuMM,Albanese C, AndersonCM,Hilty K,Webb P, Uht RM, et al. Opposing
action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol
Chem (2002) 277:24353–60. doi:10.1074/jbc.M201829200
18. Pettersson K, Delaunay F, Gustafsson JA. Estrogen receptor beta acts as a
dominant regulator of estrogen signaling. Oncogene (2000) 19:4970–8. doi:10.
1038/sj.onc.1203828
19. Lindberg MK, Movérare S, Skrtic S, Gao H, Dahlman-Wright K, Gustafsson
JA, et al. Estrogen receptor (ER)-beta reduces ERalpha-regulated gene tran-
scription, supporting a “ying yang” relationship between ERalpha and ERbeta
in mice.Mol Endocrinol (2003) 17:203–8. doi:10.1210/me.2002-0206
20. Ogawa S, Eng V, Taylor J, Lubahn DB, Korach KS, Pfaff DW. Roles of estrogen
receptor-alpha gene expression in reproduction-related behaviors in female
mice. Endocrinology (1998) 139:5070–81. doi:10.1210/endo.139.12.6357
21. Weihua Z, Saji S, Mäkinen S, Cheng G, Jensen EV, Warner M, et al. Estrogen
receptor (ER) beta, a modulator of ERalpha in the uterus. Proc Natl Acad Sci
U S A (2000) 97:5936–41. doi:10.1073/pnas.97.11.5936
22. Veeneman GH. Non-steroidal subtype selective estrogens. Curr Med Chem
(2005) 12:1077–136. doi:10.2174/0929867053764662
23. Balaguer P, François F, Comunale F, Fenet H, Boussioux AM, Pons M, et al.
Reporter cell lines to study the estrogenic effects of xenoestrogens. Sci Total
Environ (1999) 233:47–56. doi:10.1016/S0048-9697(99)00178-3
24. Docquier A, Garcia A, Savatier J, Boulahtouf A, Bonnet S, Bellet V, et al.
Negative regulation of estrogen signaling by ERβ andRIP140 in ovarian cancer
cells.Mol Endocrinol (2013) 27:1429–41. doi:10.1210/me.2012-1351
25. KojimaM, Fukunaga K, Sasaki M, NakamuraM, Tsuji M, Nishiyama T. Evalu-
ation of estrogenic activities of pesticides using an in vitro reporter gene assay.
Int J Environ Health Res (2005) 15:271–80. doi:10.1080/09603120500155765
26. Wilson VS, Bobseine K, Gray LE Jr. Development and characterization of a
cell line that stably expresses an estrogen-responsive luciferase reporter for
the detection of estrogen receptor agonist and antagonists. Toxicol Sci (2004)
81:69–77. doi:10.1093/toxsci/kfh180
27. Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson J, Nilsson S. Differ-
ential response of estrogen receptor alpha and estrogen receptor beta to partial
estrogen agonists/antagonists.Mol Pharmacol (1998) 54:105–12.
Frontiers in Endocrinology | www.frontiersin.org May 2015 | Volume 6 | Article 629
Grimaldi et al. Nuclear receptor reporter cell lines
28. Shanle EK, Hawse JR, Xu W. Generation of stable reporter breast cancer cell
lines for the identification of ER subtype selective ligands. Biochem Pharmacol
(2011) 82:1940–9. doi:10.1016/j.bcp.2011.08.026
29. van der Burg B,Winter R,WeimerM, Berckmans P, Suzuki G, Gijsbers L, et al.
Optimization and prevalidation of the in vitro ERalpha CALUXmethod to test
estrogenic and antiestrogenic activity of compounds. Reprod Toxicol (2010)
30:73–80. doi:10.1016/j.reprotox.2010.04.007
30. Escande A, Pillon A, Servant N, Cravedi JP, Larrea F, Muhn P, et al. Evaluation
of ligand selectivity using reporter cell lines stably expressing estrogen receptor
alpha or beta. Biochem Pharmacol (2006) 71:1459–69. doi:10.1016/j.bcp.2006.
02.002
31. Molina-Molina JM, Real M, Jimenez-Diaz I, Belhassen H, Hedhili A, Torné P,
et al. Assessment of estrogenic and anti-androgenic activities of the mycotoxin
zearalenone and its metabolites using in vitro receptor-specific bioassays. Food
Chem Toxicol (2014) 74C:233–9. doi:10.1016/j.fct.2014.10.008
32. Delfosse V, Grimaldi M, Cavaillès V, Balaguer P, Bourguet W. Structural and
functional profiling of environmental ligands for estrogen receptors. Environ
Health Perspect (2014) 122:1306–13. doi:10.1289/ehp.1408453
33. Gomez E, Pillon A, Fenet H, Rosain D, Duchesne MJ, Nicolas JC, et al.
Estrogenic activity of cosmetic components in reporter cell lines: parabens,
UV screens, and musks. J Toxicol Environ Health A (2005) 68:239–51. doi:10.
1080/15287390590895054
34. Molina-Molina JM, Escande A, Pillon A, Gomez E, Pakdel F, Cavaillès V,
et al. Profiling of benzophenone derivatives using fish and human estro-
gen receptor-specific in vitro bioassays. Toxicol Appl Pharmacol (2008)
232:384–95. doi:10.1016/j.taap.2008.07.017
35. Delfosse V, Grimaldi M, Pons JL, Boulahtouf A, le Maire A, Cavailles V, et al.
Structural and mechanistic insights into bisphenols action provide guidelines
for risk assessment and discovery of bisphenol A substitutes. Proc Natl Acad
Sci U S A (2012) 109:14930–5. doi:10.1073/pnas.1203574109
36. Molina-Molina JM, Amaya E, Grimaldi M, Sáenz JM, Real M,
Fernández MF, et al. In vitro study on the agonistic and antagonistic
activities of bisphenol-S and other bisphenol-A congeners and derivatives
via nuclear receptors. Toxicol Appl Pharmacol (2013) 272:127–36.
doi:10.1016/j.taap.2013.05.015
37. Riu A, le Maire A, Grimaldi M, Audebert M, Hillenweck A, Bourguet W,
et al. Characterization of novel ligands of ERα, ERβ, and PPARγ: the case of
halogenated bisphenol A and their conjugated metabolites. Toxicol Sci (2011)
122:372–82. doi:10.1093/toxsci/kfr132
38. Matsumoto T, Sakari M, Okada M, Yokoyama A, Takahashi S, Kouzmenko A,
et al. The androgen receptor in health and disease. Annu Rev Physiol (2013)
75:201–24. doi:10.1146/annurev-physiol-030212-183656
39. He B, Kemppainen JA, Wilson EM. FXXLF and WXXLF sequences mediate
the NH2-terminal interaction with the ligand binding domain of the androgen
receptor. J Biol Chem (2000) 275:22986–94. doi:10.1074/jbc.M002807200
40. WilsonVS, Bobseine K, Lambright CR, Gray LE Jr. A novel cell line,MDA-kb2,
that stably expresses an androgen- and glucocorticoid-responsive reporter for
the detection of hormone receptor agonists and antagonists. Toxicol Sci (2002)
66:69–81. doi:10.1093/toxsci/66.1.69
41. Térouanne B, Tahiri B, Georget V, Belon C, Poujol N, Avances C, et al. A stable
prostatic bioluminescent cell line to investigate androgen and antiandrogen
effects. Mol Cell Endocrinol (2000) 160:39–49. doi:10.1016/S0303-7207(99)
00251-8
42. Paris F, Servant N, Térouanne B, Sultan C. Evaluation of androgenic bioac-
tivity in human serum by recombinant cell line: preliminary results. Mol Cell
Endocrinol (2002) 198:123–9. doi:10.1016/S0303-7207(02)00375-1
43. Aït-Aïssa S, Laskowski S, Laville N, Porcher JM, Brion F. Anti-androgenic
activities of environmental pesticides in the MDA-kb2 reporter cell line.
Toxicol In vitro (2010) 24:1979–85. doi:10.1016/j.tiv.2010.08.014
44. Molina-Molina JM, Hillenweck A, Jouanin I, Zalko D, Cravedi JP, Fernández
MF, et al. Steroid receptor profiling of vinclozolin and its primary metabolites.
Toxicol Appl Pharmacol (2006) 216:44–54. doi:10.1016/j.taap.2006.04.005
45. Christen V, Crettaz P, Oberli-Schrämmli A, Fent K. Antiandrogenic activity of
phthalate mixtures: validity of concentration addition. Toxicol Appl Pharmacol
(2012) 259:169–76. doi:10.1016/j.taap.2011.12.021
46. Christen V, Crettaz P, Fent K. Additive and synergistic antiandrogenic activ-
ities of mixtures of azol fungicides and vinclozolin. Toxicol Appl Pharmacol
(2014) 279:455–66. doi:10.1016/j.taap.2014.06.025
47. Bellet V, Hernandez-Raquet G, Dagnino S, Seree L, Pardon P, Bancon-
MontinyC, et al. Occurrence of androgens in sewage treatment plants influents
is associated with antagonist activities on other steroid receptors. Water Res
(2012) 46:1912–22. doi:10.1016/j.watres.2012.01.013
48. Creusot N, Aït-Aïssa S, Tapie N, Pardon P, Brion F, Sanchez W, et al. Iden-
tification of synthetic steroids in river water downstream from pharmaceu-
tical manufacture discharges based on a bioanalytical approach and passive
sampling. Environ Sci Technol (2014) 48:3649–57. doi:10.1021/es405313r
49. van der Burg B, Winter R, Man HY, Vangenechten C, Berckmans P, Weimer
M, et al. Optimization and prevalidation of the in vitro AR CALUX method
to test androgenic and antiandrogenic activity of compounds. Reprod Toxicol
(2010) 30:18–24. doi:10.1016/j.reprotox.2010.04.012
50. Sultan C, Balaguer P, Terouanne B, Georget V, Paris F, Jeandel C, et al.
Environmental xenoestrogens, antiandrogens and disorders of male sex-
ual differentiation. Mol Cell Endocrinol (2001) 178:99–105. doi:10.1016/
S0303-7207(01)00430-0
51. Giguère V. To ERR in the estrogen pathway. Trends Endocrinol Metab (2002)
13:220–5. doi:10.1016/S1043-2760(02)00592-1
52. Bookout AL, Jeong Y, Downes M, Yu RT, Evans RM, Mangelsdorf DJ.
Anatomical profiling of nuclear receptor expression reveals a hierarchical
transcriptional network. Cell (2006) 126:789–99. doi:10.1016/j.cell.2006.06.
049
53. Audet-Walsh E, Giguére V. Themultiple universes of estrogen-related receptor
α and γ in metabolic control and related diseases. Acta Pharmacol Sin (2015)
36:51–61. doi:10.1038/aps.2014.121
54. Baillie-Hamilton PF. Chemical toxins: a hypothesis to explain the global
obesity epidemic. J Altern Complement Med (2002) 8:185–92. doi:10.1089/
107555302317371479
55. Ijichi N, Shigekawa T, Ikeda K, Horie-Inoue K, Fujimura T, Tsuda H, et al.
Estrogen-related receptor γmodulates cell proliferation and estrogen signaling
in breast cancer. J Steroid Biochem Mol Biol (2011) 123:1–7. doi:10.1016/j.
jsbmb.2010.09.002
56. Lu D, Kiriyama Y, Lee KY, Giguere V. Transcriptional regulation of the
estrogen-inducible pS2 breast cancermarker gene by the ERR family of orphan
nuclear receptors. Cancer Res (2001) 61:6755–61.
57. Vanacker JM, Pettersson K, Gustafsson JA, Laudet V. Transcriptional targets
shared by estrogen receptor-related receptors (ERRs) and estrogen receptor
(ER) alpha, but not by ERbeta. EMBO J (1999) 18:4270–9. doi:10.1093/emboj/
18.15.4270
58. Ariazi EA, Clark GM,Mertz JE. Estrogen-related receptor alpha and estrogen-
related receptor gamma associate with unfavorable and favorable biomarkers,
respectively, in human breast cancer. Cancer Res (2002) 62:6510–8.
59. Yu S, Wang X, Ng CF, Chen S, Chan FL. ERRgamma suppresses cell
proliferation and tumor growth of androgen-sensitive and androgen-
insensitive prostate cancer cells and its implication as a therapeutic target
for prostate cancer. Cancer Res (2007) 67:4904–14. doi:10.1158/0008-5472.
CAN-06-3855
60. Greschik H, Wurtz JM, Sanglier S, Bourguet W, van Dorsselaer A, Moras D,
et al. Structural and functional evidence for ligand-independent transcrip-
tional activation by the estrogen-related receptor 3.Mol Cell (2002) 9:303–13.
doi:10.1016/S1097-2765(02)00444-6
61. Li J, Ma M, Wang Z. In vitro profiling of endocrine disrupting effects of
phenols. Toxicol In vitro (2010) 24:201–7. doi:10.1016/j.tiv.2009.09.008
62. Okada H, Tokunaga T, Liu X, Takayanagi S, Matsushima A, Shimohigashi Y.
Direct evidence revealing structural elements essential for the high binding
ability of bisphenol A to human estrogen-related receptor-gamma. Environ
Health Perspect (2008) 116:32–8. doi:10.1289/ehp.10587
63. Suetsugi M, Su L, Karlsberg K, Yuan YC, Chen S. Flavone and isoflavone
phytoestrogens are agonists of estrogen related receptors. Mol Cancer Res
(2003) 1:981–91.
64. Yang C, Chen S. Two organochlorine pesticides, toxaphene and chlordane, are
antagonists for estrogen related receptor alpha-1 orphan receptor. Cancer Res
(1999) 59:4519–24.
65. Wang J, Fang F, Huang Z, Wang Y, Wong C. Kaempferol is an estrogen-
related receptor alpha and gamma inverse agonist.FEBSLett (2009) 5:83643–7.
doi:10.1016/j.febslet.2009.01.030
66. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med
(2002) 53:409–35. doi:10.1146/annurev.med.53.082901.104018
Frontiers in Endocrinology | www.frontiersin.org May 2015 | Volume 6 | Article 6210
Grimaldi et al. Nuclear receptor reporter cell lines
67. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, et al.
International union of pharmacology. LXI. Peroxisome proliferator-activated
receptors. Pharmacol Rev (2006) 58:726–41. doi:10.1124/pr.58.4.5
68. Varga T, Czimmerer Z, Nagy L. PPARs are a unique set of fatty acid regulated
transcription factors controlling both lipid metabolism and inflammation.
Biochim Biophys Acta (2011) 1812:1007–22. doi:10.1016/j.bbadis.2011.02.014
69. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of
PPARgamma. Annu Rev Biochem (2008) 77:289–312. doi:10.1146/annurev.
biochem.77.061307.091829
70. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, et al. PPARγ
signaling and metabolism: the good, the bad and the future. Nat Med (2013)
19:557–66. doi:10.1038/nm.3159
71. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear
control of metabolism. Endocr Rev (1999) 20:649–88. doi:10.1210/edrv.20.5.
0380
72. le Maire A, Grimaldi M, Roecklin D, Dagnino S, Vivat-Hannah V, Balaguer
P, et al. Activation of RXR-PPAR heterodimers by organotin environmen-
tal endocrine disruptors. EMBO Rep (2009) 10:367–73. doi:10.1038/embor.
2009.8
73. Riu A, Grimaldi M, le Maire A, Bey G, Phillips K, Boulahtouf A, et al.
Peroxisome proliferator-activated receptor γ is a target for halogenated analogs
of bisphenol A. Environ Health Perspect (2011) 119:1227–32. doi:10.1289/ehp.
1003328
74. Janesick A, Blumberg B. Minireview: PPARgamma as the target of obesogens.
J Steroid Biochem Mol Biol (2011) 127:4–8. doi:10.1016/j.jsbmb.2011.01.005
75. Grun F, Blumberg B. Endocrine disrupters as obesogens. Mol Cell Endocrinol
(2009) 304:19–29. doi:10.1016/j.mce.2009.02.018
76. Janesick A, Blumberg B. Obesogens, stem cells and the developmental pro-
gramming of obesity. Int J Androl (2012) 35:437–48. doi:10.1111/j.1365-2605.
2012.01247.x
77. Gijsbers L, Man HY, Kloet SK, de Haan LH, Keijer J, Rietjens IM, et al. Stable
reporter cell lines for peroxisome proliferator-activated receptor γ (PPARγ)-
mediated modulation of gene expression. Anal Biochem (2011) 414:77–83.
doi:10.1016/j.ab.2011.02.032
78. Seimandi M, Lemaire G, Pillon A, Perrin A, Carlavan I, Voegel JJ, et al.
Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter
cell lines to selective PPAR synthetic ligands. Anal Biochem (2005) 344:8–15.
doi:10.1016/j.ab.2005.06.010
79. Zoeller TR, Dowling AL, Herzig CT, Iannacone EA, Gauger KJ, Bansal R.
Thyroid hormone, brain development, and the environment. Environ Health
Perspect (2002) 110:355–61. doi:10.1289/ehp.02110s3355
80. Bernal J. Thyroid hormone receptors in brain development and function. Nat
Clin Pract Endocrinol Metab (2007) 3:249–59. doi:10.1038/ncpendmet0424
81. Crofton KM. Thyroid disrupting chemicals: mechanisms and mixtures. Int J
Androl (2008) 31:209–23. doi:10.1111/j.1365-2605.2007.00857.x
82. Freitas J, Cano P, Craig-Veit C, Goodson ML, Furlow JD, Murk AJ. Detection
of thyroid hormone receptor disruptors by a novel stable in vitro reporter gene
assay. Toxicol In vitro (2011) 25:257–66. doi:10.1016/j.tiv.2010.08.013
83. Jugan ML, Lévy-Bimbot M, Pomérance M, Tamisier-Karolak S, Blondeau JP,
Lévi Y. A new bioluminescent cellular assay to measure the transcriptional
effects of chemicals that modulate the alpha-1 thyroid hormone receptor.
Toxicol In vitro (2007) 21:1197–205. doi:10.1016/j.tiv.2007.03.020
84. Fini JB, Riu A, Debrauwer L, Hillenweck A, Le Mével S, Chevolleau S, et al.
Parallel biotransformation of tetrabromobisphenol A in Xenopus laevis and
mammals: Xenopus as a model for endocrine perturbation studies. Toxicol Sci
(2012) 125:359–67. doi:10.1093/toxsci/kfr312
85. Orans J, Teotico DG, Redinbo MR. The nuclear xenobiotic receptor preg-
nane X receptor: recent insights and new challenges. Mol Endocrinol (2005)
19:2891–900. doi:10.1210/me.2005-0156
86. di Masi A, De Marinis E, Ascenzi P, Marino M. Nuclear receptors CAR and
PXR: molecular, functional, and biomedical aspects. Mol Aspects Med (2009)
30:297–343. doi:10.1016/j.mam.2009.04.002
87. Mikamo E, Harada S, Nishikawa J, Nishihara T. Endocrine disruptors induce
cytochrome P450 by affecting transcriptional regulation via pregnane X recep-
tor. Toxicol Appl Pharmacol (2003) 193:66–72. doi:10.1016/j.taap.2003.08.001
88. Sui Y, Park SH, Helsley RN, Sunkara M, Gonzalez FJ, Morris AJ, et al.
Bisphenol A increases atherosclerosis in pregnane X receptor-humanized
ApoE deficient mice. J Am Heart Assoc (2014) 3:e000492. doi:10.1161/JAHA.
113.000492
89. Chaturvedi NK, Kumar S, Negi S, Tyagi RK. Endocrine disruptors provoke
differential modulatory responses on androgen receptor and pregnane and
xenobiotic receptor: potential implications in metabolic disorders. Mol Cell
Biochem (2010) 345:291–308. doi:10.1007/s11010-010-0583-6
90. Banerjee M, Robbins D, Chen T. Targeting xenobiotic receptors PXR and
CAR in human diseases.Drug Discov Today (2014). doi:10.1016/j.drudis.2014.
11.011
91. Wang H, Venkatesh M, Li H, Goetz R, Mukherjee S, Biswas A, et al. Preg-
nane X receptor activation induces FGF19-dependent tumor aggressiveness
in humans and mice. J Clin Invest (2011) 121:3220–32. doi:10.1172/JCI41514
92. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA.
The human orphan nuclear receptor PXR is activated by compounds that
regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest
(1998) 102:1016–23. doi:10.1172/JCI3703
93. Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR
coordinately regulates drug metabolism and efflux. Nat Med (2001) 7:584–90.
doi:10.1038/87912
94. Watkins RE, Maglich JM, Moore LB, Wisely GB, Noble SM, Davis-Searles PR,
et al. A crystal structure of human PXR in complex with the St. John’s wort
compoundhyperforin.Biochemistry (2003) 42:1430–8. doi:10.1021/bi0268753
95. Wentworth JM, AgostiniM, Love J, Schwabe JW, Chatterjee VK. St John’s wort,
a herbal antidepressant, activates the steroid X receptor. J Endocrinol (2000)
166:R11–6. doi:10.1677/joe.0.166R011
96. Lemaire G, de Sousa G, Rahmani R. A PXR reporter gene assay in a stable
cell culture system: CYP3A4 and CYP2B6 induction by pesticides. Biochem
Pharmacol (2004) 68:2347–58. doi:10.1016/j.bcp.2004.07.041
97. Ratajewski M, Grzelak I, Wisniewska K, Ryba K, Gorzkiewicz M, Walczak-
Drzewiecka A, et al. Screening of a chemical library reveals novel PXR-
activating pharmacologic compounds. Toxicol Lett (2014) 232:193–202.
doi:10.1016/j.toxlet.2014.10.009
98. Raucy J, Warfe L, Yueh MF, Allen SW. A cell-based reporter gene assay for
determining induction of CYP3A4 in a high-volume system. J Pharmacol Exp
Ther (2002) 303:412–23. doi:10.1124/jpet.102.038653
99. Sekimoto M, Sano S, Hosaka T, Nemoto K, Degawa M. Establishment of a
stable human cell line, HPL-A3, for use in reporter gene assays of cytochrome
P450 3A inducers. Biol Pharm Bull (2012) 35:677–85. doi:10.1248/bpb.35.677
100. Lemaire G, Mnif W, Mauvais P, Balaguer P, Rahmani R. Activation of alpha-
and beta-estrogen receptors by persistent pesticides in reporter cell lines. Life
Sci (2006) 79:1160–9. doi:10.1016/j.lfs.2006.03.023
101. Lemaire G, Mnif W, Pascussi JM, Pillon A, Rabenoelina F, Fenet H, et al.
Identification of new human pregnane X receptor ligands among pesticides
using a stable reporter cell system. Toxicol Sci (2006) 91:501–9. doi:10.1093/
toxsci/kfj173
102. Mnif W, Pascussi JM, Pillon A, Escande A, Bartegi A, Nicolas JC, et al.
Estrogens and antiestrogens activate hPXR. Toxicol Lett (2007) 170:19–29.
doi:10.1016/j.toxlet.2006.11.016
103. Creusot N, Kinani S, Balaguer P, Tapie N, LeMenach K, Maillot-Maréchal E,
et al. Evaluation of an hPXR reporter gene assay for the detection of aquatic
emerging pollutants: screening of chemicals and application to water samples.
Anal Bioanal Chem (2010) 396:569–83.
104. Mangelsdorf DJ, Evans RM. The RXR heterodimers and orphan receptors.Cell
(1995) 83:841–50. doi:10.1016/0092-8674(95)90200-7
105. Germain P, Iyer J, Zechel C, Gronemeyer H. Co-regulator recruitment and
the mechanism of retinoic acid receptor synergy. Nature (2002) 415:187–92.
doi:10.1038/415187a
106. HeymanRA,Mangelsdorf DJ, Dyck JA, Stein RB, Eichele G, Evans RM, et al. 9-
cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell (1992)
68:397–406. doi:10.1016/0092-8674(92)90479-V
107. de Urquiza AM, Liu S, Sjoberg M, Zetterstrom RH, Griffiths W, Sjovall J, et al.
Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain.
Science (2000) 290:2140–4. doi:10.1126/science.290.5499.2140
108. Nahoum V, Pérez E, Germain P, Rodríguez-Barrios F, Manzo F, Kammerer
S, et al. Modulators of the structural dynamics of the retinoid X receptor
to reveal receptor function. Proc Natl Acad Sci U S A (2007) 104:17323–8.
doi:10.1073/pnas.0705356104
109. Alonso-Magdalena P, Ropero AB, Soriano S, García-Arévalo M, Ripoll C,
Fuentes E, et al. Bisphenol-A acts as a potent estrogen via non-classical
estrogen triggered pathways. Mol Cell Endocrinol (2012) 355:201–7. doi:10.
1016/j.mce.2011.12.012
Frontiers in Endocrinology | www.frontiersin.org May 2015 | Volume 6 | Article 6211
Grimaldi et al. Nuclear receptor reporter cell lines
110. Ajj H, Chesnel A, Pinel S, Plenat F, Flament S, Dumond H. An alkylphenol
mix promotes seminoma derived cell proliferation through an ERalpha36-
mediated mechanism. PLoS One (2013) 8:e61758. doi:10.1371/journal.pone.
0061758
111. Chevalier N, Vega A, Bouskine A, Siddeek B, Michiels JF, Chevallier D, et al.
GPR30, the non-classical membrane G protein related estrogen receptor, is
overexpressed in human seminoma and promotes seminoma cell proliferation.
PLoS One (2012) 7:e34672. doi:10.1371/journal.pone.0034672
112. Kortenkamp A. Low dose mixture effects of endocrine disrupters and their
implications for regulatory thresholds in chemical risk assessment. Curr Opin
Pharmacol (2014) 19:105–11. doi:10.1016/j.coph.2014.08.006
113. Montes-Grajales D, Olivero-Verbel J. Computer-aided identification of novel
protein targets of bisphenol A. Toxicol Lett (2013) 222:312–20. doi:10.1016/j.
toxlet.2013.08.010
114. McRobb FM, Kufareva I, Abagyan R. In silico identification and pharma-
cological evaluation of novel endocrine disrupting chemicals that act via
the ligand-binding domain of the estrogen receptor α. Toxicol Sci (2014)
141:188–97. doi:10.1093/toxsci/kfu114
115. Vuorinen A, Odermatt A, Schuster D. In silico methods in the discovery of
endocrine disrupting chemicals. J Steroid BiochemMol Biol (2013) 137:18–26.
doi:10.1016/j.jsbmb.2013.04.009
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015 Grimaldi, Boulahtouf, Delfosse, Thouennon, Bourguet and Bal-
aguer. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in other
forums is permitted, provided the original author(s) or licensor are credited and that
the original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply with
these terms.
Frontiers in Endocrinology | www.frontiersin.org May 2015 | Volume 6 | Article 6212
